Hims & Hers Health (NYSE:HIMS) Posts Earnings Results, Misses Expectations By $0.44 EPS

Posted by on May 12th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) posted its earnings results on Monday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44), FiscalAI reports. The firm had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.20 earnings per share.

Here are the key takeaways from Hims & Hers Health’s conference call:

  • Hims & Hers pivoted its weight‑loss strategy to branded GLP‑1s and quickly partnered with Novo Nordisk—fulfilling more than 125,000 Wegovy shipments and signaling it is on track to add north of 100,000 new weight‑loss subscribers per month.
  • Q1 showed modest top‑line growth (revenue $608M, +4%; subscribers ~2.6M, +9%) but the company incurred approximately $33 million of restructuring charges (including ~$28M write‑downs) tied to the GLP‑1 compounding pivot, resulting in a GAAP loss of $92M and ~5 percentage points of gross‑margin pressure.
  • Management raised 2026 guidance to $2.8–$3.0 billion in revenue and $275–$350 million in adjusted EBITDA (≈11% margin at midpoint), expecting accelerating revenue and EBITDA in H2 as monthly cohorts compound and marketing efficiency improves.
  • The company is investing heavily in AI and data infrastructure—building provider and consumer AI copilots, growing an in‑house AI team, and acquiring YourBio for at‑home blood sampling—to strengthen a proprietary data flywheel that management says will deepen engagement and create a durable competitive advantage.
  • International expansion is a strategic focus—Hims & Hers expects the Eucalyptus acquisition to close in H2 (≈$240M initial payment) to broaden its global footprint and support its long‑term 2030 targets of at least $6.5 billion revenue and $1.3 billion adjusted EBITDA.

Hims & Hers Health Trading Up 3.0%

HIMS opened at $29.12 on Tuesday. The stock’s fifty day moving average is $23.08 and its two-hundred day moving average is $29.44. The company has a market capitalization of $6.64 billion, a P/E ratio of 57.10, a PEG ratio of 3.85 and a beta of 2.43. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. TD Cowen lowered their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Evercore set a $24.00 target price on Hims & Hers Health in a research report on Tuesday, February 24th. Leerink Partners increased their target price on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Finally, Morgan Stanley lowered their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $31.86.

View Our Latest Research Report on HIMS

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 204,857 shares of company stock valued at $5,285,706. Company insiders own 13.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the 1st quarter valued at $30,000. Greenline Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at $36,000. DV Equities LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at $46,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Featured Stories

Earnings History for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.